Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia

Critical Reviews in Oncology/Hematology

Volumn 25, Issue 1, 1997, Pages 11-26

  Pieters, R ^a   Klumper, E ^a   Kaspers, G J L ^a   Veerman, A J P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACLARUBICIN; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLUCOCORTICOID; IFOSFAMIDE; MAFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; TENIPOSIDE; TIOGUANINE; VERAPAMIL; VINCA ALKALOID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD; HUMAN; MULTIDRUG RESISTANCE; REVIEW;

ANTINEOPLASTIC AGENTS; CHILD; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1;

EID: 0030889437     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(96)00223-5     Document Type: Review

References (178)

1. [1] Chessels JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 89:364-372, 1995.
2. [2] Poplack DG, Reaman G. Acute lymphoblastic leukemia in childhood. Pediatr Clin North Am 35:903-932, 1988.
3. [3] Schorin MA, Blattner S, Gelber RD et al. Treatment of childhood acute lymphoblastic leukemia: results of the Dana-Farber Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740-747, 1994.
4. [4] Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G. Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis. Haematol Blood Transf 30:139-146, 1987.
5. [5] Pui CH. Childhood leukemia. N Engl J Med 332:1618-1630, 1995.
6. [6] Veerman AJP, Hählen K, Kamps WA, Leeuwen van EF, Vaan de GAM, Solbu G, Suciu S, Wering van ER, Does van der-Berg van den A. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911-918, 1996.
7. [7] Evans WE, Petros WP, Relling MV et al. Clinical pharmacology of cancer chemotherapy in children. Pediatr Clin N Am 36:1199-1230, 1989.
8. [8] Evans WE, Rodman J, Relling MV et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 28 (Suppl 4):15-21, 1991.
9. [9] Veerman AJP, Pieters R. Drug sensitivity assays in leukaemia and lymphoma. Br J Haematol 74:381-384, 1990.
10. [10] Mattern J, Volm M. Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treat Rev 9:267-298, 1982.
11. [11] Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 69:615-632, 1985.
12. [12] Twentyman PR. Predictive chemosensitivity testing. Br J Cancer 51:295-299, 1985.
13. [13] McGuire WL, Kern DH, Von Hoff DD, Weisenthal LM. In vitro assays to predict drug sensitivity and drug resistance. Breast Cancer Res Treat 12:7-21, 1988.
14. [14] Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82:582-588, 1990.
15. [15] Hongo T, Fujii Y, Mizuno Y, Haraguchi S, Yoshida TO. Anticancer drug sensitivity test using the short-term microplate culture and MTT dye reduction assay. Jpn J Cancer Chemother 14:472-478, 1987.
16. [16] Hongo T, Fujii Y, Igarashi Y. An in vitro chemosensitivity test for the screening of anticancer drugs in childhood leukemia. Cancer 65:1263-1272, 1990.
17. [17] Pieters R, Huismans DR, Leyva A, Veerman AJP. Adaptation of the rapid automated tetrazolium dye based MTT assay for chemosensitivity testing in childhood leukemia. Cancer Lett 41:323-332, 1988.
18. [18] Pieters R, Huismans DR, Leyva A, Veerman AJP. Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia. Br J Cancer 59:217-220, 1989.
19. [19] Pieters R, Loonen AH, Huismans DR et al. In vitro sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76:2327-2336, 1990.
20. [20] Weisenthal LM, Marsden JA, Dill PL, Macaluso CK. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 43:749-757, 1983.
21. [21] Bird MC, Bosanquet AG, Gilby ED. In vitro determination of tumour chemosensitivity in haematological malignancies. Hematol Oncol 3:1-9, 1985.
22. [22] Larsson R, Nygren P, Ekberg M, Slater L. Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semi-automated fluorometric assay. Leukemia 4:567-571, 1990.
23. [23] Kaspers GJL, Veerman AJP, Pieters R et al. Mononuclear cells contaminating leukemic samples tested for cellular drug resistance using the MTT assay. Br J Cancer 70:1047-1052, 1994.
24. [24] Dow LW, Dahl GV, Kalwinsky DK, Mirro J, Nash MB, Roberson PK. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia. Blood 68:400-405, 1986.
25. [25] Smith PJ, Lihou MG. Prediction of remission induction in childhood acute myeloid leukemia. Aust NZ J Med 16:39-42, 1986.
26. [26] Delmer A, Marie J-P, Thevenin D, Cadiou M, Viguié F, Zittoun R. Multivariate analysis of prognostic factors in acute myeloid leukemia: Value of clonogenic leukemic cell properties. J Clin Oncol 7:738-746, 1989.
27. [27] Gustavsson A, Olofsson T. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells. Cancer Res 44:4648-4652, 1984.
28. [28] Park CH, Amare M, Savin MA, Goodwin JW, Newcomb MM, Hoogstraten B. Prediction of chemotherapy response in human leukemia using an in vitro chemotherapy sensitivity test on the leukemic colony-forming cells. Blood 55:595-601, 1980.
29. [29] Park CH, Wiernik PH, Morrison FS, Amare M, Van Sloten K, Maloney TR. Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs. Cancer Res 43:2346-2349, 1983.
30. [30] Hongo T, Fujii Y. In vitro chemosensitivity of lymphoblasts at relapse in childhood leukemia using the MTT assay. Int J Hematol 54:219-230, 1991.
31. [31] Pieters R, Huismans DR, Loonen AH, Hählen K, Van Der Does-Van Den Berg A, Van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338:399-403, 1991.
32. [32] Kaspers GJL, R Pieters, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJP. Resistance to prednisolone (PRD) in vitro: A new prognostic factor in childhood acute lymphoblastic leukemia (ALL) at initial diagnosis. Proc Am Soc Clin Oncol 12:320 (abstract), 1993.
33. [33] Veerman AJP, Kaspers GJL, Klumper E, Pieters R. Drug resistance risk assignment in childhood acute lymphoblastic leukemia. Int J Ped Hematol Oncol (in press).
34. [34] Nagourney RA, Groney PK, Oseas RS, Finkelstein JZ, Weisenthal LM. Glucocorticoid sensitivity assessed in vitro: a new prognostic factor for relapse in childhood acute lymphoblastic leukemia. Proc Am Soc Clin Oncol 7:715 (abstract), 1988.
35. [35] Hwang W-S, Chen L-M, Huang S-H, Wang C-C, Tseng MT. Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity test. Leuk Res 17:685-688, 1993.
36. [36] Santini V, Bernabei PA, Silvestro L et al. In vitro chemosensitivity testing of leukemic cells: Prediction of response to chemotherapy in patients with acute nonlymphocytic leukemia. Hematol Oncol 7:287-293, 1989.
37. [37] Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 60:206-210, 1989.
38. [38] Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorimetric microculture cytotoxicity assay (FMCA). Int J Cancer 50:177-185, 1992.
39. [39] Beksac M, Kansu E, Kars A, Ibrahimoglu Z, Firat D. A rapid drug sensitivity assay for neoplasmatic cells. Med Oncol Tumor Pharmacother 5:253-257, 1988.
40. [40] Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet 337:711-714, 1991.
41. [41] Lathan B, Von Tettau M, Verpoort K, Diehl V. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. Haematol Blood Transf 33:295-298, 1990.
42. [42] Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. In vitro drug testing in patients mimicking in vivo intracellular drug concentrations. Eur J Haematol 43:374-384, 1989.
43. [43] Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep 70:1283-1295, 1986.
44. [44] Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metast Rev 11:121-139, 1992.
45. [45] Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80:879-886, 1992.
46. [46] Kaspers GJL, Pieters R, Klumper E, de Waal FC, Veerman AJP. Glucocorticoid resistance in childhood leukemia. Leuk Lymph 13:187-201, 1994.
47. [47] Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular and clinical considerations. J Ped Hemat Oncol 17:1-12, 1995.
48. [48] Moalli PA, Rosen ST. Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk Lymph 15:363-374, 1994.
49. [49] Riehm H, Reiter A, Schrappe M et al. Die corticosteroid-abhängige dezimierung der leukämiezellzahl im blut als prognosefaktor bei der akuten lymphoblastischen leukämie im kindesalter (therapiestudie ALL-BFM 83). Klin Pädiatr 199:151-160, 1986.
50. [50] Bohinjec J. A test with dexamethasone in acute leukemia. Blut 35:289-294, 1977.
51. [51] Mastrangelo R, Riccardi R, Corbo S, Marchetti P, Iacobelli S. Prediction of clinical response to glucocorticoids in children with acute lymphoblastic leukemia. Eur J Paediatr Haematol Oncol 1:33-36, 1984.
52. [52] Pui C-H, Dahl GV, Rivera G, Murphy SB, Costlow ME. The relationship of blast cell glucocorticoid receptor level to response to single-agent steroid trial and remission response in children with acute lymphoblastic leukemia. Leuk Res 8:579-585, 1984.
53. [53] Reiter A, Schrappe M, Sauter S et al. Treatment strategy and results of non-B acute lymphoblastic leukemia in the German-Austrian multicenter trial ALL NHL-BFM 86. Med Pediatr Oncol 20:390 (abstract), 1992.
54. [54] Kaspers GJL, Pieters R, van Zantwijk CH et al. Is resistance to prednisolone in vitro related to the response to prednisone in vivo at initial diagnosis in childhood acute lymphoblastic leukemia? A preliminary analysis. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma - The Clinical Value of Laboratory Studies. Chur, Harwood Academic Publishers. 1993: 321-328.
55. [55] Pieters R, Kaspers GJL, van Wering ER et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 3:392-397, 1993.
56. [56] Costlow ME, Pui C-H, Dahl GV. Glucocorticoid receptors in childhood acute lymphoblastic leukemia. Cancer Res 42:4801-4806, 1982.
57. [57] Konior-Yarbro GS, Lippman ME, Johnson GE, Leventhal BG. Glucocorticoid receptors in subpopulations of childhood acute lymphocytic leukemia. Cancer Res 37:2688-2695, 1977.
58. [58] Pui C-H, Costlow ME. Sequential analysis of lymphoblast glucocorticoid receptor levels at diagnosis and relapse in childhood leukemia: An update. Leuk Res 10:227-229, 1986.
59. [59] Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, Borowitz MJ. Glucocorticoid receptors in immunological sub-types of childhood acute lymphocytic leukemia cells: A Pediatric Oncology Group study. Cancer Res 45:6482-6486, 1985.
60. [60] Sherman MS, Stevens YW, Tuazon FB. Multiple forms and fragments of cytosolic glucocorticoid receptors from human leukemic cells and normal lymphocytes. Cancer Res 44:3783-3796, 1984.
61. [61] Vogler LB, Crist WM, Sarrif AM et al. Analysis of clinical and laboratory features of acute lymphocytic leukemias with emphasis on 35 children with pre-B-leukemia. Blood 58:135-140, 1981.
62. [62] Galili N, Galili U. Glucocorticoid-induced lysis of various subsets of acute lymphoblastic leukemia. Haematol Blood Transfus 28:146-147, 1983.
63. [63] Pieters R, Hongo T, Loonen AH et al. Non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukemia. Br J Cancer 65:691-697, 1992.
64. [64] Klumper E, Pieters R, Veerman AJP et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86:3861-3868, 1995.
65. [65] Ho AD, Hunstein W, Ganeshaguru K, Hoffbrand AV, Brandeis WE, Denk B. Therapeutic and prognostic implications of glucocorticoid receptors and terminal deoxynucleotidyl transferase in acute leukemia. Leuk Res 6:1-8, 1982.
66. [66] Pui C-H, Ochs J, Kalwinsky DK, Costlow ME. Impact of treatment efficacy on the prognostic value of glucocorticoid receptor levels in childhood acute lymphoblastic leukemia. Leuk Res 8:345 350, 1984.
67. [67] Mastrangelo R, Malandrino R, Riccardi R, Longo P, Ranelletti FO, Iacobelli S. Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia. Blood 56:1036-1040, 1980.
68. [68] Marchetti P, Natoli V, Ranelletti FO, Mandelli F, de Rossi G, Iacobelli S. Glucocorticoid receptor studies in human leukemia. J Steroid Biochem 15:261-268, 1981.
69. [69] Lippman ME, Konior G, Leventhal BG. Clinical implications of glucocorticoid receptors in human leukemia. Cancer Res 38:4251-4256, 1978.
70. [70] Federico MHH, Martins VR, Pozzi DHB, Llacer PED, Brenatni MM. Glucocorticoid receptors in acute leukemia. Braz J Biol Res 19:167-172, 1986.
71. [71] Gerstein YS, Smirnova KD, Moiseyenko YI, Bassalyk LS. Prognostic significance of glucocorticoid receptor level in bone marrow blast cells of pediatric leukemia patients. Voprosy Onkologii 33:20-24, 1987.
72. [72] Iacobelli S, Marchetti P, De Rossi G, Mandelli F, Gentiloni N. Glucocorticoid receptors predict response to combination chemotherapy in patients with acute lymphoblastic leukemia. Oncology 44:13-16, 1987.
73. [73] Kato GJ, Quddus FF, Shuster JJ et al. High glucorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 82:2304-2309, 1993.
74. [74] Pui C-H, Costlow ME, Dahl GV, Rivera GK, Murphy SB. Response of recurrent acute lymphoblastic leukemia to glucocorticoids: Serial studies of receptor content, in vivo cytokinetic changes and clinical responses. Leuk Res 7:747-753, 1983.
75. [75] Pui CH, Costlow ME, Kalwinsky DK, Dahl GV. Glucocorticoid receptors in childhood acute non-lymphocytic leukemia. Leukemia 7:11-16, 1983.
76. [76] Kaspers GJL, Kardos G, Pieters R et al. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: A pilot study. Leukemia 8:1224-1229, 1994.
77. [77] Kaspers GJL, Pieters R, Van Zantwijk CH et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64:469-474, 1991.
78. [78] Costlow ME, Pui C-H. Nuclear translocation of lymphoblast glucocorticoid receptors in childhood leukemia does not predict steroid responsiveness. J Steroid Biochem 26:15-18, 1987.
79. [79] Kaspers GJL, Veerman AJP, Popp-Snijders C et al. A comparison of the antileukemic activity in vitro of prednisolone and dexamethasone in childhood acute lymphoblastic leukemia. Med Ped Oncol 1996 27:114-121, 1996.
80. [80] Jones B, Freeman AI, Shuster J et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19:269-275, 1991.
81. [81] Balis FM, Lester C, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5:202-207, 1987.
82. [82] Choonara I, Wheeldon J, Rayner P, Blackburn M, Lewis I. Pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol, 23:392-394 1989.
83. [83] Richter O, Ern B, Reinhardt D, Becker B. Pharmacokinetics of dexamethasone in children. Pediatr Pharmacol 3:329-337, 1983.
84. [84] Cline MJ, Rosenbaum E. Prediction of in vivo cytotoxicity of chemotherapeutic agents by their in vitro effect on leukocytes from patients with acute leukemia. Cancer Res 28:2516-2521, 1968.
85. [85] Asselin BL, Ryan D, Frantz CN et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 49:4363-4368, 1989.
86. [86] Kiriyama Y, Kubota M, Takimoto T et al. Biochemical characterization of U937 cells resistant to L-asparaginase: The role of asparagine synthetase. Leukemia 3:294-297, 1989.
87. [87] Prager MD, Bachynsky N. Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase. Arch Biochem Biophys 127:645-654, 1968.
88. [88] Oettgen HF, Schulten HK. Hemmung maligner neoplasien des menschen durch L-asparagine. Klin Wochenschr 47:65, 1969.
89. [89] Haskell CM, Canellos GP. L-Asparaginase resistance in human leukemia-Asparagine synthetase. Biochem Pharmacol 18:2578-2580, 1969.
90. [90] Hughes JM, Tattersall MHN. Modulation of antifolate cytotoxicity by metabolites from dying cells in a lymphocyte clonal assay. Br J Cancer 57:459-463, 1988.
91. [91] Haber M, Madafiglio J, Norris MD. Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine. J Cancer Res Clin Oncol 119:315-317, 1993.
92. [92] Rodenhuis S, McGuire JJ, Narayanan R, Bertino JR. Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res 46:6513-6519, 1986.
93. [93] Pieters R, Rots M, van Zantwijk CH et al. Determination of methotrexate resistance in childhood leukemia and the role of folylpolyglutamate hydrolase (FPGH). Proc Am Ass Cancer Res 37:336 (# 2295), 1996.
94. [94] Trippett T, Schlemmer S, Elisseyeff Y et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 80:1158-1162, 1992.
95. [95] Gorlick R, Göker E, Trippett E, Eliseyeff Y, Flintoff W, Bertino JR. Decreased reduced folate carrier expression is observed in human leukemic blasts with defective methotrexate transport. Proc Am Ass Cancer Res 37:317 (# 2155), 1996.
96. [96] Whitehead VM, Rosenblatt DS, Vuhich M-J, Shuster JJ, Witte A, Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 76:44-49, 1990.
97. [97] Whitehead VM, Vuhich M-J, Lauer SJ et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid ( > 50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 80:1316-1323, 1992.
98. [98] Göker E, Lin JT, Trippett T et al. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 7:1000-1004, 1993.
99. [99] Synold TW, Relling MV, Boyett JM et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996-2001, 1994.
100. [100] Masson E, Relling MV, Synold TW et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J Clin Invest 97:73-80, 1996.
101. [101] Lin JT, Tong WP, Trippett TM et al. Basis for natural resistance to methotrexate in human acute non-lymphoblastic leukemia. Leuk Res 15:1191-1196, 1991.
102. [102] Yamauchi H, Iwata N, Omine M, Maekawa T. In vitro methotrexate polyglutamate formation is elevated in acute lymphoid leukemia cells compared with acute myeloid leukemia and normal bone marrow cells. Acta Haematol Japonica 51:766-773, 1988.
103. [103] Alt FW, Kellems RE, Bertino JR, Schimke RT. Multiplication of dihydrofblate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357-1370, 1978.
104. [104] Ohnuma T, Lo RJ, Scanlon KJ et al. Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro. Cancer Res 45:1815-1822, 1985.
105. [105] Dedhar S, Hartley D, Goldie JH. Increased dihydrofolate reductase activity in methotrexate-resistant promyelocytic-leukemia (HL-60) cells. Biochem J 225:609-617, 1985.
106. [106] Van der Laan BFAM. Jansen G, Kathmann I, Schornagel JH, Hordijk GJ. Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedules. Eur J Cancer 27:1274-1278, 1991.
107. [107] Rothenberg ML, Mickley LA, Cole DE et al. Expression of the mdr-1/p-170 gene in patients with acute lymphoblastic leukemia. Blood 74:1388-1395, 1989.
108. [108] Göker E, Waltham M, Kheradpour A et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated wilh p53 gene mutations. Blood 86:677-684, 1995.
109. [109] Matherly LH, Taub JW, Ravindranath Y et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resislance in childhood acute lymphoblastic leukemia. Blood 85:500-509, 1995.
110. [110] Kaspers GJL, Smets LA, Pieters R, van Zantwijk CH, van Wering ER, Veerman AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to other antimetabolites and other drugs: Results of an in vitro study. Blood 85:751-756, 1995.
111. [111] Adamson PC, Poplack DG, Balls FM. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 18:805-810, 1994.
112. [112] Nelson JA, Carpenter JW, Rose LM, Adamson DJ. Mechanisms of action of 6-thioguanine, 6-mercaptopurine and 8-azaguanine. Cancer Res 35:2872-2878, 1975.
113. [113] Bökkerink JPM. New aspects of methotrexate and 6-mercaptopurine. Potential synergism and biochemical pharmacology in human malignant lymphoblasts. Thesis, Catholic University Nijmegen. The Netherlands, 1987.
114. [114] Veerman AJP, Hogeman PHG, van Zantwijk CH, Bezemer PD. Prognostic value of 5′nucleotidase in acute lymphoblastic leukemia with the common-ALL phenotype. Leuk Res 9:1227-1229, 1985.
115. [115] Pieters R, Thompson LF, Broekema GJ et al. Expression of 5′-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage. Blood 78:488-492, 1991.
116. [116] Pieters R, Huismans DR, Loonen AH et al. Relation of nucleotidase and phosphatase activities with drug resistance and clinical prognosis in childhood leukemia. Leuk Res 16:873-880, 1992.
117. [117] Zimm S, Johnson GE, Poplack DG. Modulation of thiopurine cytotoxicity in the HL-60 cell line by physiological concentrations of hypoxanthine. Cancer Res 46:6286-6289, 1986.
118. [118] Wolpert MK, Damle SP, Brown JE, Sznycer E, Agrawal KC, Sartorelli AC. The role of phosphohydrolases in the mechanism of resistance of neoplastic ceils to 6-thiopurines. Cancer Res 31:1620-1626, 1971.
119. [119] Lee MH, Huang Y-M, Sartorelli AC. Alkaline phosphatase activities of 6-thiopurine-sensitive and -resistance sublines of sarcoma 180. Cancer Res 38:2413-2418, 1978.
120. [120] Rosman M, Lee MH, Creasy WA, Sartorelli AC. Mechanisms of resistance to 6-thiopurines in human leukemia. Cancer Res 34:1952-1956, 1974.
121. [121] Zimm S, Johnson GE, Chabner BA, Poplack DG. Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines. Cancer Res 45:4156, 1985.
122. [122] van der Does-van den Berg A, van Wering ER, Suciu S et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: Results of a Dutch phase III study (ALL V). Am J Ped Hematol Oncol 11:125-133, 1989.
123. [123] Basso G, Agostino C, Cocito MG et al. Non-T, Non-B childhood acute lymphoblastic leukemia. Correlation between cytochemical markers and first complete remission. Cancer 54:981, 1984.
124. [124] Pieters R, Veerman AJP. Prognostic significance of acid alpha-naphthyl acetate esterase and acid phosphatase in childhood leukemia. Leuk Res 11:995-999, 1987.
125. [125] Pieters R, Huismans DR, Loonen AH et al. Adenosine deaminase and purine nucleoside phosphorylase in childhood leukemia: relation with differentiation stage, clinical prognosis and in vitro drug resistance. Leukemia 6:375-380, 1992.
126. [126] Peters GJ, Oosterhof A, Veerkamp JH. Effects of adenosine and deoxyadenosine on PHA-stimulation of lymphocytes of man, horse and pig. Int J Biochem 14:377-385, 1982.
127. [127] Snyder FF, Hershfield MS, Seegmiller JE. Cytotoxic and metabolic effects of adenosine and adenine on human lymphoblasts. Cancer Res 38:2357-2362, 1978.
128. [128] Zimm S, Reaman G, Murphy RF, Poplack DG. Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia. Cancer Res 46:1495-1498, 1986.
129. [129] Davidson JD. Studies on the mechanism of action of 6-mercaptopurine in sensitive and resistance L1210 leukemia in vitro. Cancer Res 20:225-232, 1960.
130. [130] Brockman RW. A mechanism of resistance to 6-mercaptopurine: metabolism of hypoxanthine and 6-mercaptopurine by sensitive and resistant neoplasms. Cancer Res 20:643-653, 1960.
131. [131] Ellis DB, LePage GA. Biochemical studies of resistance to 6-thioguanine. Cancer Res 23:436-443, 1963.
132. [132] Brockman RW. Resistance to purine antagonists in experimental leukemia systems. Cancer Res 25:1596-1605, 1965.
133. [133] Curt GA, Clendeninn NJ, Chabner BA. Drug resistance in cancer. Cancer Treat Rep 68:87-99, 1984.
134. [134] Hall A, Cattan AR, Proctor SJ. Mechanism of drug resistance in acute leukaemia. Leuk Res 13:351-356, 1989.
135. [135] Davidson JD, Winter TS. Purine nucleotide pyrophosphorylases in 6-mercaptopurine-sensitive and -resistant human leukemias. Cancer Res 24:261-267, 1964.
136. [136] Kessel D, Hall TC. Retention of 6-mercaptopurine derivatives by intact cells as an index of drug response in human and murine leukemias. Cancer Res 29:2116-2119, 1969.
137. [137] Pieters R, Huismans DR, Loonen AH et al. Hypoxanthine-guanine phosphoribosyltransferase in childhood leukemia: relation with immunophenotype, differentiation stage, in vitro drug resistance and clinical prognosis. Int J Cancer 51:213-217, 1992.
138. [138] Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood acute lymphoblastic leukaemia. J Clin Oncol 7:1816-1823, 1989.
139. [139] Lennard L, van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukaemia; Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41:18-24, 1987.
140. [140] Boos J, Hohenlöchter B, Schulze-Westhoff P et al. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Med Ped Oncol 26:397-404, 1996.
141. [141] Kohl U, Schwabbe D, Viusschedyk K, Rohrbach E, Cinatl J, Kornhuber B. Accumulation of intracellular cytosine-arabinoside-5′-triphosphate in leukemic bone marrow cells of pediatric patients with reference to normal lymphatic cells. Ann Hematol 68 (suppl I):A23 (abstract 92), 1994.
142. [142] Kees UR, Ford J, Dawson VM, Piall E, Aherene GW. Development of resistance to 1-β-D-Arabinofuranosylcytosine after high-dose treatment in childhood acute lymphoblastic leukemia: Analysis of resistance mechanism in established cell lines. Cancer Res 49:3015-3019, 1989.
143. [143] Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Veertnan AJP. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 19:407-417, 1995.
144. [144] Kaspers GJL, Veerman AJP, Pieters R, van Zantwijk CH, Klumper E, Hählen K, de Waal FC, van Wering ER. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia 8,24-29, 1994.
145. [145] Klumper E, Pieters R, den Boer ML et al. In vitro anthracycline cross-resistance patterns in childhood acute lymphoblastic leukemia. Br J Cancer 71:1188-1193, 1995.
146. [146] May GL, Wright LC, Dyne M, Mackinnon WB, Fox RM, Mountford CE. Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts. Int J Cancer 42:728-733, 1988.
147. [147] Kingreen D, Sperling C, Notter M et al. Sequential analysis of P-glycoprotein expression in childhood acute lymphoblastic leukemia. Haematol Blood Transf 34:23-28, 1992.
148. [148] Goasguen JE, Dossot J-M, Fardel O et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications. Blood 81:2394, 1993.
149. [149] Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase π in childhood acute lymphoblastic leukaemia. Br J Cancer 70:1144-1149, 1994.
150. [150] Ivy SP, Sather HN, Hammond GD, Reaman GH. The prognostic significance of MDR1 gene expression at diagnosis in childhood acute lymphoblastic leukemia. Pediatric Res 33:141A, 1993.
151. [151] Brophy NA, Marie JP, Rojas VA et al. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: A critical evaluation by four techniques. Leukemia 8:327-335, 1994.
152. [152] Gekeler V, Frese G, Noller A et al. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase π gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer 66:507-517, 1992.
153. [153] Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr1. mrp. topoisomerase IIχ/β and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haemat 89:356-353, 1995.
154. [154] Ivy SP, Smith JK, Speciale A, Sather H, Hammond GD, Reaman GH. Detection of mdr1 gene expression using polymerase chain reaction (PCR) in childhood acute lymphoblastic leukemia (ALL) at diagnosis. Proc Am Ass Cancer Res 33:473 (abstract 2826), 1992.
155. [155] Ubezio P, Limonta M, d'Incalci M et al. Failure to detect the p-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia. Eur J Cancer Clin Oncol 25:1895-1899, 1989.
156. [156] Tawa A, Ishihara S, Yumura K et al. Expression of the multidrug-resistance gene in childhood leukemia. Jpn J Pediatr Hematol 4:38-43, 1990.
157. [157] Mizuno Y, Hara T, Nagata M, Tawa A, Tsuruo T, Ueda K. Detection of multidrug-resistant protein. P-glycoprotein in childhood leukaemia and lymphoma. Eur J Pediatr 150:416-418, 1991.
158. [158] O'Meara A, Imamura A, Johnson P et al. Reactivity of P-glycoprotein monoclonal antibodies in childhood cancers. Oncology 49:203-208, 1992.
159. [159] Drach D, Zhao S, Drach J et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729-2734, 1992.
160. [160] Chaudray PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resislance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735-2739, 1992.
161. [161] Damiani D, Michieli M, Michelutti A et al. Expression of multidrug resistance gene (MDR-1) in human normal leukocytes. Haematologica 78:12-17, 1993.
162. [162] Rivera-Fillat MP, Pallares-Trujillo J, Domenech C, Grau-Oliete MR. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine. Br J Pharmacol 93:902-908, 1988.
163. [163] Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650, 1992.
164. [164] Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural products. Cancer Res 54:357, 1994.
165. [165] Krishnamachary N. Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190 kDa membrane bound glycoprotein. Cancer Res 53:3658, 1993.
166. [166] List AF, Spier CS, Abbaszadegan M et al. Non-P-glycoprotein (PGP) mediated multidrug resistance (MDR): Identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia (AML). Proc ASH 1993, Blood (suppl 1):443a, 1993.
167. [167] Scheper RJ, Broxterman HJ, Scheffer GL et al. Overexpression of a Mr 110000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475, 1993.
168. [168] Zaman GJR, Versantvoort CHM, Smit JJM et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53:1747, 1993.
169. [169] den Boer ML, Pieters R, Kazemier KM et al. LRP but not P-gp or MRP may cause drug resistance in childhood ALL. Proc Am Ass Cancer Res 37:319 (#2174), 1996.
170. [170] Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833-4836, 1994.
171. [171] Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72:82-89, 1995.
172. [172] Klumper E, Giaccone G, Pieters R et al. Topoisomerase IIχ gene expression in childhood acute lymphoblastic leukemia. Leukemia 9:1653-1660, 1995.
173. [173] Stammler G, Sauerbrey A, Volm M. Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblastic leukemia. Cancer Lett 89:129-135, 1995.
174. [174] Uckun FM, Chandan-Langlie M, Dockham PA, Aeppli D, Sladek NE. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide. Leuk Lymph 13:417-418, 1994.
175. [175] Hall AG, Tilby MJ. Mechanisms of action of and modes of resistance to. alkylating agents used in the treatment of haematological malignancies. Blood Rev 6:163-173, 1992.
176. [176] Maung ZT, Hogarth L, Reid MM, Proctor SJ, Hamilton PJ, Hall AG. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukaemia. Leukemia 8:1487-1491, 1994.
177. [177] Hall A, Foster S, Proctor SJ, Cattan AR. Purification and characterization of a pi class glutathione S-transferase from human leukemic cells. Br J Haematol 76:494-500, 1990.
178. [178] Hall AG, Autzen P, Cattan AR, et al. Expression μ class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia. Cancer Res 54:5251-5254, 1994.